84703-18-4

Usage

Uses

Used in Pharmaceutical Synthesis:
5-Bromo-2-chloro-6-methylnicotinonitrile is used as an intermediate in the production of drugs and other chemical substances. Its unique structure allows for the creation of a variety of biologically active molecules, making it a valuable component in the development of new pharmaceuticals.
Used in Agrochemical Production:
In the agrochemical industry, 5-Bromo-2-chloro-6-methylnicotinonitrile is utilized as a key intermediate for the synthesis of various agrochemicals. Its ability to form stable and effective compounds contributes to its significance in this field.
Used in Medicinal Chemistry Research:
5-Bromo-2-chloro-6-methylnicotinonitrile is studied for its potential antiviral and antioxidant properties. Its presence in the development of compounds with these properties highlights its importance in the advancement of medicinal chemistry and the search for novel therapeutic agents.
Used in the Synthesis of Biologically Active Molecules:
As a versatile building block, 5-Bromo-2-chloro-6-methylnicotinonitrile is employed in the synthesis of a wide range of biologically active molecules. Its structural diversity and reactivity make it a preferred choice for researchers working on the development of new compounds with potential therapeutic applications.

InChI:InChI=1S/C7H4BrClN2/c1-4-6(8)2-5(3-10)7(9)11-4/h2H,1H3

Upstream product

• 51146-04-4 ethyl 2-hydroxy-6-methylpyridine-3-carboxylate 
• 38116-61-9 2-hydroxy-6-methylnicotinic acid 
• 4241-27-4 1,2-dihydro-6-methyl-2-oxo-3-pyridinecarbonitrile 
• 84725-13-3 5-bromo-6-methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile 
• 4241-27-4 2-hydroxy-6-methylnicotinonitrile 
• 84725-13-3 5-bromo-2-hydroxy-6-methylnicotinonitrile 

Downstream Products

• 90713-69-2 5-Bromo-2-anilino-6-methylnicotinic acid 
• 90713-66-9 2-Anilino-5-bromo-6-methylnicotinonitrile 

Relevant academic research and scientific papers

IMIDAZOPYRIMIDINES AS EED INHIBITORS AND THE USE THEREOF

The present disclosure provides compounds represented by Formula (I) wherein R1, R2, R3, and R4 are as defined in the specification, and the salts and solvates thereof. Compounds of Formula (I) are FED inhibitors. FED inhibitors are useful for the treatment of cancer and other diseases.

Discovery and optimization of thienopyridine derivatives as novel urea transporter inhibitors

Urea transporters (UTs) play an important role in the urine concentrating mechanism and are recognized as novel targets for developing small molecule inhibitors with salt-sparing diuretic activity. Thienoquinoline derivatives, a class of novel UT-B inhibitors identified by our group, play a significant diuresis in animal model. However, the poor solubility and low bioavailability limited its further development. To overcome these shortcomings, the structure modification of thienoquinoline was carried out in this study, which led to the discovery of novel thienopyridine derivatives as specific urea transporter inhibitors. Further optimization obtained the promising preclinical candidate 8n with not only excellent inhibition effect on urea transporters and diuretic activity on rat model, but also suitable water solubility and Log P value.

PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS

Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R4, R5, R6, R5, G1, and G2 are defined herein.

THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS

The disclosure relates to inhibitors of USP28 and/or USP25 useful in the treatment of cancers, inflammation, autoimmune diseases, and infectious diseases, having the Formula (I), where R1, R2, R3, R4, R5, R5', R6, R7, X, m, and n are described herein.

N-ACYLPIPERIDINE ETHER TROPOMYOSIN-RELATED KINASE INHIBITORS

The present invention relates to compounds of Formula (I) described herein and their pharmaceutically acceptable salts, and their use in medicine, in particular as Trk antagonists.